O'Sullivan, C. C., Kalinsky, K., Yau, C., Wallace, A. M., Chien, J., Yee, D., Boughey, J. C., Borges, V. F., Nanda, R., Isaacs, C., Omene, C., Kulkarni, T., Swigart, L. B., Perlmutter, J., Hylton, N., Borowsky, A. D., Shatsky, R. A., Rugo, H. S., Veer, L. V., Esserman, L. (2026). Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba514